Correction to: Nature Reviews Endocrinology, published online 17 April 2024

In the version of the article initially published, in the “GLP1RAs and cardiorenal risk” section, the sentence now reading “A dedicated trial studying the effects of weekly 1 mg semaglutide on renal outcomes …” originally read “2.4 mg semaglutide” and has now been amended in the HTML and PDF versions of the article.